Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Could Positon Emission Tomography With Radiolabelled 3'-Deoxy-3'-(18)F-Fluoro-L-Thymidine be a Theranostic Tool During Erlotinib Treatment in Non-small Cell Lung Cancer Patients ?

NCT02069418 is registered in ClinicalTrials.gov with University Hospital, Angers as lead sponsor.

NCT NCT02069418
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02069418 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Could Positon Emission Tomography With Radiolabelled 3'-Deoxy-3'-(18)F-Fluoro-L-Thymidine be a Theranostic Tool During Erlotinib Treatment in Non-small Cell Lung Cancer Patients ?
Lead sponsor
University Hospital, Angers
Phase
Phase 2
Overall status
Unknown status
Start date
February 28, 2014
Completion date
June 30, 2016
Enrollment
80 (estimated)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

no egfr activating mutation, non-small cell lung cancer metastatic or non-small cell lung cancer recurrent